$ACON

Bond Ryan purchased $50K of ACON

Bond Ryan purchased 21,122 shares of Aclarion, Inc. (ACON) at $2.37 on 2026-08-13.

Original reporting
SEC EDGAR · Bond Ryan
Published Aug 17, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The disclosed buy may modestly improve sentiment, but it does not introduce new guidance, financial results, contracts, or regulatory developments.

02

Market read

Traders may note the insider buy, but the filing alone is unlikely to drive a durable repricing without accompanying company fundamentals.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on compensation, prior holdings, or future trading intentions.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-13

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Aclarion, Inc.

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

Bond Ryan, a director of Aclarion, bought 21,122 shares in an open-market transaction on 2026-08-13 for about $50,059.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing provides transaction size, price, and post-transaction holdings, but no new company-specific operational or financial information.

Market effects

No sector-level implications disclosed; this is a single-insider transaction.

None indicated.

None indicated.

Counterpoint

A director open-market purchase without a 10b5-1 plan can still be routine and may not signal a change in fundamentals.

Key entities

  • Aclarion, Inc.

    Company subject of the Form 4 insider transaction disclosure (ACON).

  • Bond Ryan

    Director who purchased 21,122 shares open-market on 2026-08-13.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.